Shopping Cart 0
Cart Subtotal
USD 0

Amneal Pharmaceuticals Inc (AMRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Amneal Pharmaceuticals Inc (Amneal) formerly Amneal Pharmaceuticals LLC, is an integrated specialty pharmaceutical company that produces generic, specialty and biosimilar medicines. Its product portfolio includes generic and specialty drugs in the therapeutic areas of analgesic, antibiotic, antiepileptic, antihypertensive, anti-inflammatory, cough suppressant, vitamin supplement, cholinergic agonist, immunosuppressant and urinary antiseptic, among others. The company offers products in various dosage forms such as oral solids and liquids, injectables, topicals, creams and ointments, transdermals, inhalation, ophthalmic and otic liquids and other device driven products. Amneal also offers services which include product research and development, active pharmaceutical ingredient (API) manufacturing, packaging, distribution and account management. The company has operational facilities across the US, India and Ireland as well as commercial offices in Switzerland, Germany, the UK, Australia, Spain, Germany, Switzerland and Scandinavia. Amneal is headquartered in Bridgewater, New Jersey, the US.

Amneal Pharmaceuticals Inc (AMRX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

Amneal Pharma Acquires Generic Business of Actavis Australia 13

Amneal Pharma Acquires Four Generic Products from Actavis for USD10 Million 14

Partnerships 16

Amneal Pharma Enters into Licensing Agreement with mAbxience 16

Merger 17

Amneal Merges with Impax 17

Licensing Agreements 19

Amneal Pharma Enters into Licensing Agreement with Jerome Stevens Pharma 19

Amneal Pharma Enters into Licensing Agreement with Adello Biologics 20

Amneal Pharma Enters into Development and Licensing Agreement with Iconovo 21

Amneal Pharma Enters Into Licensing Agreement With Hanmi Pharma For Nexium Alternative 22

Equity Offering 23

Amneal Pharma Plans to Raise Funds through Public Offering of Shares 23

Amneal Pharma to Raise USD854 Million in Private Placement of Shares 24

Debt Offering 25

Amneal Pharma Raises USD600 Million in Private Placement of 2% Notes Due 2022 25

Asset Transactions 26

ANI Pharma to Acquire Generic Products from Amneal Pharma and Impax Labs 26

ANI Pharma to Acquire Manufacturing Equipment from Amneal Pharma and Impax Labs 28

Acquisition 29

Aristo Pharma Acquires Amneal Nordic and Amneal Pharma Spain 29

Novartis May Acquire Amneal Pharma 30

Amneal Pharma Plans to Acquire Epsilon Pharma for up to USD16.9 Million 31

Amneal Pharmaceuticals Inc-Key Competitors 32

Amneal Pharmaceuticals Inc-Key Employees 33

Amneal Pharmaceuticals Inc-Locations And Subsidiaries 34

Head Office 34

Other Locations & Subsidiaries 34

Recent Developments 36

Financial Announcements 36

Aug 09, 2018: Amneal Announces Solid Second Quarter 2018 Financial Results 36

Mar 02, 2018: Amneal 4th Quarter Full Year 2017 Quarterly Financial Report 39

Corporate Communications 42

Feb 06, 2018: Andrew S. Boyer Joins Amneal Pharmaceuticals as Executive Vice President, Commercial Operations 42

Dec 18, 2017: Robert Stewart to Join Amneal Pharma as President 43

Dec 18, 2017: Robert Stewart to Join Amneal Pharmaceuticals as President 44

Clinical Trials 45

Apr 21, 2017: Impax to Present Data on Investigational Drug IPX203 at the 2017 American Academy of Neurology Annual Meeting 45

Other Significant Developments 46

May 11, 2018: Amneal Announces Actions to Streamline Operations and Capture Cost Synergies 46

Jan 23, 2018: PSEG Long Island Presents Amneal Facility with Energy-Efficiency Rebates 47

Appendix 48

Methodology 48

About GlobalData 48

Contact Us 48

Disclaimer 48


List Of Figure

List of Figures

Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Amneal Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Amneal Pharma Acquires Generic Business of Actavis Australia 13

Amneal Pharma Acquires Four Generic Products from Actavis for USD10 Million 14

Amneal Pharma Enters into Licensing Agreement with mAbxience 16

Amneal Merges with Impax 17

Amneal Pharma Enters into Licensing Agreement with Jerome Stevens Pharma 19

Amneal Pharma Enters into Licensing Agreement with Adello Biologics 20

Amneal Pharma Enters into Development and Licensing Agreement with Iconovo 21

Amneal Pharma Enters Into Licensing Agreement With Hanmi Pharma For Nexium Alternative 22

Amneal Pharma Plans to Raise Funds through Public Offering of Shares 23

Amneal Pharma to Raise USD854 Million in Private Placement of Shares 24

Amneal Pharma Raises USD600 Million in Private Placement of 2% Notes Due 2022 25

ANI Pharma to Acquire Generic Products from Amneal Pharma and Impax Labs 26

ANI Pharma to Acquire Manufacturing Equipment from Amneal Pharma and Impax Labs 28

Aristo Pharma Acquires Amneal Nordic and Amneal Pharma Spain 29

Novartis May Acquire Amneal Pharma 30

Amneal Pharma Plans to Acquire Epsilon Pharma for up to USD16.9 Million 31

Amneal Pharmaceuticals Inc, Key Competitors 32

Amneal Pharmaceuticals Inc, Key Employees 33

Amneal Pharmaceuticals Inc, Other Locations 34

Amneal Pharmaceuticals Inc, Subsidiaries 34

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Amneal Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Amneal Pharmaceuticals Inc (Amneal) formerly Amneal Pharmaceuticals LLC, is an integrated specialty pharmaceutical company that produces generic, specialty and biosimilar medicines. Its product portfolio includes generic and specialty drugs in the therapeutic areas of analgesic, antibiotic, antiepileptic, antihypertensive, anti-inflammatory, cough suppressant, vitamin supplement, cholinergic agonist, immunosuppressant and urinary antiseptic, among others. The company offers products in various dosage forms such as oral solids and liquids, injectables, topicals, creams and ointments, transdermals, inhalation, ophthalmic and otic liquids and other device driven products. Amneal also offers services which include product research and development, active pharmaceutical ingredient (API) manufacturing, packaging, distribution and account management. The company has operational facilities across the US, India and Ireland as well as commercial offices in Switzerland, Germany, the UK, Australia, Spain, Germany, Switzerland and Scandinavia. Amneal is headquartered in Bridgewater, New Jersey, the US.

Amneal Pharmaceuticals Inc (AMRX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

Amneal Pharma Acquires Generic Business of Actavis Australia 13

Amneal Pharma Acquires Four Generic Products from Actavis for USD10 Million 14

Partnerships 16

Amneal Pharma Enters into Licensing Agreement with mAbxience 16

Merger 17

Amneal Merges with Impax 17

Licensing Agreements 19

Amneal Pharma Enters into Licensing Agreement with Jerome Stevens Pharma 19

Amneal Pharma Enters into Licensing Agreement with Adello Biologics 20

Amneal Pharma Enters into Development and Licensing Agreement with Iconovo 21

Amneal Pharma Enters Into Licensing Agreement With Hanmi Pharma For Nexium Alternative 22

Equity Offering 23

Amneal Pharma Plans to Raise Funds through Public Offering of Shares 23

Amneal Pharma to Raise USD854 Million in Private Placement of Shares 24

Debt Offering 25

Amneal Pharma Raises USD600 Million in Private Placement of 2% Notes Due 2022 25

Asset Transactions 26

ANI Pharma to Acquire Generic Products from Amneal Pharma and Impax Labs 26

ANI Pharma to Acquire Manufacturing Equipment from Amneal Pharma and Impax Labs 28

Acquisition 29

Aristo Pharma Acquires Amneal Nordic and Amneal Pharma Spain 29

Novartis May Acquire Amneal Pharma 30

Amneal Pharma Plans to Acquire Epsilon Pharma for up to USD16.9 Million 31

Amneal Pharmaceuticals Inc-Key Competitors 32

Amneal Pharmaceuticals Inc-Key Employees 33

Amneal Pharmaceuticals Inc-Locations And Subsidiaries 34

Head Office 34

Other Locations & Subsidiaries 34

Recent Developments 36

Financial Announcements 36

Aug 09, 2018: Amneal Announces Solid Second Quarter 2018 Financial Results 36

Mar 02, 2018: Amneal 4th Quarter Full Year 2017 Quarterly Financial Report 39

Corporate Communications 42

Feb 06, 2018: Andrew S. Boyer Joins Amneal Pharmaceuticals as Executive Vice President, Commercial Operations 42

Dec 18, 2017: Robert Stewart to Join Amneal Pharma as President 43

Dec 18, 2017: Robert Stewart to Join Amneal Pharmaceuticals as President 44

Clinical Trials 45

Apr 21, 2017: Impax to Present Data on Investigational Drug IPX203 at the 2017 American Academy of Neurology Annual Meeting 45

Other Significant Developments 46

May 11, 2018: Amneal Announces Actions to Streamline Operations and Capture Cost Synergies 46

Jan 23, 2018: PSEG Long Island Presents Amneal Facility with Energy-Efficiency Rebates 47

Appendix 48

Methodology 48

About GlobalData 48

Contact Us 48

Disclaimer 48


List Of Figure

List of Figures

Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Amneal Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Amneal Pharma Acquires Generic Business of Actavis Australia 13

Amneal Pharma Acquires Four Generic Products from Actavis for USD10 Million 14

Amneal Pharma Enters into Licensing Agreement with mAbxience 16

Amneal Merges with Impax 17

Amneal Pharma Enters into Licensing Agreement with Jerome Stevens Pharma 19

Amneal Pharma Enters into Licensing Agreement with Adello Biologics 20

Amneal Pharma Enters into Development and Licensing Agreement with Iconovo 21

Amneal Pharma Enters Into Licensing Agreement With Hanmi Pharma For Nexium Alternative 22

Amneal Pharma Plans to Raise Funds through Public Offering of Shares 23

Amneal Pharma to Raise USD854 Million in Private Placement of Shares 24

Amneal Pharma Raises USD600 Million in Private Placement of 2% Notes Due 2022 25

ANI Pharma to Acquire Generic Products from Amneal Pharma and Impax Labs 26

ANI Pharma to Acquire Manufacturing Equipment from Amneal Pharma and Impax Labs 28

Aristo Pharma Acquires Amneal Nordic and Amneal Pharma Spain 29

Novartis May Acquire Amneal Pharma 30

Amneal Pharma Plans to Acquire Epsilon Pharma for up to USD16.9 Million 31

Amneal Pharmaceuticals Inc, Key Competitors 32

Amneal Pharmaceuticals Inc, Key Employees 33

Amneal Pharmaceuticals Inc, Other Locations 34

Amneal Pharmaceuticals Inc, Subsidiaries 34

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Amneal Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.